AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Results will further underscore efficacy and safety of IMFINZI®, TAGRISSO®, and LYNPARZA® across multiple cancers with high unmet need ENHERTU data will reinforce its transformative potential in HER2-targetable cancers New data for MEDI5752 will advance the science of next-generation immunotherapy WILMINGTON, Del.–(BUSINESS WIRE)–AstraZeneca will present new data supporting its ambition to redefine cancer care at … [Read more…]
